Cheng, H H
Gulati, R
Azad, A
Nadal, R
Twardowski, P
Vaishampayan, U N
Agarwal, N
Heath, E I
Pal, S K
Rehman, H-t
Leiter, A
Batten, J A
Montgomery, R B
Galsky, M D
Antonarakis, E S
Chi, K N
Yu, E Y
Article History
Received: 10 September 2014
Revised: 3 November 2014
Accepted: 20 November 2014
First Online: 20 January 2015
Competing interests
: The coauthors declare the following conflicts of interest: AA declares research support from Astellas (Australia) and an honorarium from Janssen (Canada). RBM declares research support from Medivation/Astellas. UNV declares research support and honoraria from Medivation/Astellas. SKP declares honoraria from Medivation/Astellas and is a consultant/advisor for Dendreon. MDG declares research support from Janssen, Dendreon, BioMotiv, is a consultant/advisor to Astellas, Dendreon, BioMotiv and has equity in Dual Therapeutics. ESA is a consultant/advisor to Medivation/Astellas, Janssen Biotech and Sanofi US. KNC is a consultant/advisor to Medivation/Astellas and Janssen Biotech. EYY declares research funding from Bristol-Myers Squibb, Dendreon, GTx, Imclone/Lilly, Janssen and OncoGeneX and honoraria from Bayer, Dendreon, Janssen Biotech, Medivation/Astellas and Sanofi US. All remaining authors have declared no conflicts of interest.